Rafael Holdings Enters Standby Purchase Agreement With Chairman
12 Health Care Stocks Moving In Monday's After-Market Session
Rafael Holdings, Inc. Announces Rights Offering for Class B Common Stock Worth $25 Million
Rafael Holdings Announces Proposed Terms Of $25M Rights Offering To Support Its Commitment To Development And Potential Launch Of Trappsol Cyclo.
Express News | Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
Rafael Holdings CEO Conkling Steps Down; Replaced by Former CEO Jonas
Rafael Holdings CEO Resignation Announced
Rafael Holdings Announces Leadership Transition Following Merger With Cyclo Therapeutics and Full Enrollment of TransportNPC Phase 3 Trial for Niemann-Pick Disease Treatment
Express News | Rafael Holdings Inc - Howard Jonas to Assume Role of CEO at Rafael Holdings
Rafael Holdings: Results From 48-Week Interim Analysis Expected in Middle of 2025 >RFL
Rafael Holdings: Cyclo Therapeutics' TransportNPC Phase 3 Clinical Trial for Trappsol Cyclo for Niemann-Pick Disease Type C1 Fully Enrolled >RFL
Rafael Holdings CEO Bill Conkling Will Be Stepping Dn From His Role >RFL
Express News | Rafael Holdings Strengthens Its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down From His Role
Press Release: Rafael Holdings Strengthens Its Focus on the Development of Trappsol(R) Cyclo(TM) and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down From His Role
Express News | Rafael Holdings Inc: Files for Offering of $25,000,000 Class B Common Stock
News On Cyclo Therapeutics Inc. (CYTH) Now Under RFL
Press Release: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Express News | Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Rafael Holdings | 10-Q: Q2 2025 Earnings Report
Rafael Holdings GAAP EPS of -$0.19, Revenue of $0.07M